Proposed Response Assessment and Endpoints for Meningioma Clinical Trials: Report from the Response Assessment in Neuro-Oncology Working Group

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2018 Aug 24

PMID 30137421

Citations 91

Authors

Raymond Y Huang

Wenya Linda Bi

Michael Weller

Thomas Kaley

Jaishri Blakeley

Ian Dunn

Evanthia Galanis

Matthias Preusser

Michael McDermott

Leland Rogers

Jeffrey Raizer

David Schiff

Riccardo Soffietti

Jorg-Christian Tonn

Michael Vogelbaum

Damien Weber

David A Reardon

Patrick Y Wen

Affiliations

Soon will be listed here.

Abstract

No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.

Citing Articles

A retrospective comparison of active surveillance to stereotactic radiosurgery for the management of elderly patients with an incidental meningioma.

Hallak H, Mantziaris G, Pikis S, Islim A, Peker S, Samanci Y Acta Neurochir (Wien). 2025; 167(1):37.

PMID: 39912992 PMC: 11802698. DOI: 10.1007/s00701-025-06452-4.

Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG).

Lesueur P, Joly F, Clarisse B, Lequesne J, Stefan D, Balosso J Radiat Oncol. 2025; 20(1):16.

PMID: 39881369 PMC: 11781042. DOI: 10.1186/s13014-025-02591-1.

Effectiveness and safety of hypofractionated gamma knife radiosurgery for large meningiomas and those adjacent to the optic pathway and brainstem: preliminary therapeutic outcomes.

Hirano Y, Shinya Y, Umekawa M, Hasegawa H, Kawashima M, Wipplinger C Neurosurg Rev. 2025; 48(1):49.

PMID: 39809896 DOI: 10.1007/s10143-025-03199-5.

Identification of key elements in MRI reporting of intracranial meningiomas based on a nationwide survey of clinical experts in Germany.

Huckhagel T, Abboud T, Regelsberger J, Rieken S, Riedel C Sci Rep. 2025; 15(1):1043.

PMID: 39762278 PMC: 11704235. DOI: 10.1038/s41598-024-83737-1.

Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01).

Lesueur P, Clarisse B, Lequesne J, Licaj I, Feuvret L, Stefan D BMC Cancer. 2024; 24(1):1594.

PMID: 39736544 PMC: 11687058. DOI: 10.1186/s12885-024-13353-9.

References

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View

Ellingson B, Bendszus M, Boxerman J, Barboriak D, Erickson B, Smits M . Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015; 17(9):1188-98. PMC: 4588759. DOI: 10.1093/neuonc/nov095. View

Pearson B, Markert J, Fisher W, Guthrie B, Fiveash J, Palmer C . Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. Neurosurg Focus. 2008; 24(5):E3. DOI: 10.3171/FOC/2008/24/5/E3. View

Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J . Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014; 16(6):829-40. PMC: 4022224. DOI: 10.1093/neuonc/not330. View

Rogers L, Barani I, Chamberlain M, Kaley T, McDermott M, Raizer J . Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2014; 122(1):4-23. PMC: 5062955. DOI: 10.3171/2014.7.JNS131644. View

Wolchok J, Hoos A, ODay S, Weber J, Hamid O, Lebbe C . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624. View

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

Miyatake S, Kawabata S, Nonoguchi N, Yokoyama K, Kuroiwa T, Matsui H . Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol. 2009; 11(4):430-6. PMC: 2743223. DOI: 10.1215/15228517-2008-107. View

Goldbrunner R, Minniti G, Preusser M, Jenkinson M, Sallabanda K, Houdart E . EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016; 17(9):e383-91. DOI: 10.1016/S1470-2045(16)30321-7. View

10.

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

11.

Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W, Debus J . Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys. 2007; 68(3):858-63. DOI: 10.1016/j.ijrobp.2006.12.073. View

12.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

13.

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

14.

Lin N, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler H . Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009; 15(4):1452-9. DOI: 10.1158/1078-0432.CCR-08-1080. View

15.

Galldiks N, Albert N, Sommerauer M, Grosu A, Ganswindt U, Law I . PET imaging in patients with meningioma-report of the RANO/PET Group. Neuro Oncol. 2017; 19(12):1576-1587. PMC: 5716194. DOI: 10.1093/neuonc/nox112. View

16.

Riemenschneider M, Perry A, Reifenberger G . Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006; 5(12):1045-54. DOI: 10.1016/S1474-4422(06)70625-1. View

17.

Bauknecht H, Romano V, Rogalla P, Klingebiel R, Wolf C, Bornemann L . Intra- and interobserver variability of linear and volumetric measurements of brain metastases using contrast-enhanced magnetic resonance imaging. Invest Radiol. 2009; 45(1):49-56. DOI: 10.1097/RLI.0b013e3181c02ed5. View

18.

Wen P, Quant E, Drappatz J, Beroukhim R, Norden A . Medical therapies for meningiomas. J Neurooncol. 2010; 99(3):365-78. DOI: 10.1007/s11060-010-0349-8. View

19.

van den Bent M, Wefel J, Schiff D, Taphoorn M, Jaeckle K, Junck L . Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011; 12(6):583-93. DOI: 10.1016/S1470-2045(11)70057-2. View

20.

Pan H, Cheng F, Sun M, Chen C, Sheehan J . Prediction of volumetric data errors in patients treated with gamma knife radiosurgery. Stereotact Funct Neurosurg. 2007; 85(4):184-91. DOI: 10.1159/000101297. View